> top > docs > PubMed:1603822 > annotations

PubMed:1603822 JSONTXT

Annnotations TAB JSON ListView MergeView

jnlpba-st-training

Id Subject Object Predicate Lexical cue
T1 187-195 cell_type denotes platelet
T2 445-471 cell_type denotes peripheral blood monocytes
T3 1357-1365 cell_type denotes platelet
T4 1438-1456 protein denotes oestrogen receptor
T5 1467-1475 protein denotes collagen

genia-medco-coref

Id Subject Object Predicate Lexical cue
C1 0-11 NP denotes Eicosanoids
C2 15-37 NP denotes breast cancer patients
C3 70-111 NP denotes 19 patients with a malignant breast tumor
C4 187-207 NP denotes platelet aggregation
C5 209-215 NP denotes Values
C6 235-240 NP denotes those
C7 244-322 NP denotes patients with benign tumors (n = 4), or undergoing a mammary reduction (n = 7)
C8 416-427 NP denotes Eicosanoids
C9 528-545 NP denotes 6-keto-PGF1 alpha
C10 551-555 NP denotes PGE2
C12 628-643 NP denotes cancer patients
C11 580-643 NP denotes Differences in pre- and postoperative values of cancer patients
C13 676-680 NP denotes PGE2
C14 685-699 NP denotes 6-k-PGF1 alpha
C15 786-802 NP denotes such differences
C16 816-834 NP denotes the control groups
C17 856-903 NP denotes benign tumor or mammary reduction test material
C18 930-975 NP denotes tissue obtained from malignant mammary tumors
C19 1099-1121 NP denotes the non-tumor material
C20 1134-1162 NP denotes the malignant tumor material
C21 1357-1377 NP denotes platelet aggregation
C22 1421-1436 NP denotes ADP aggregation
C23 1480-1508 NP denotes arachidonic acid aggregation
C24 1551-1579 NP denotes arachidonic acid aggregation
C25 1603-1618 NP denotes ADP aggregation
C27 1666-1674 NP denotes material
C26 1666-1703 NP denotes material from mammary cancer patients
C29 1722-1726 NP denotes that
C28 1722-1751 NP denotes that in benign mammary tissue
R1 C3 C2 coref-other 19 patients with a malignant breast tumor,breast cancer patients
R2 C6 C5 coref-pron those,Values
R3 C8 C1 coref-ident Eicosanoids,Eicosanoids
R4 C12 C3 coref-other cancer patients,19 patients with a malignant breast tumor
R5 C13 C10 coref-ident PGE2,PGE2
R6 C14 C9 coref-ident 6-k-PGF1 alpha,6-keto-PGF1 alpha
R7 C15 C11 coref-ident such differences,Differences in pre- and postoperative values of cancer patients
R8 C16 C7 coref-ident the control groups,"patients with benign tumors (n = 4), or undergoing a mammary reduction (n = 7)"
R9 C19 C17 coref-ident the non-tumor material,benign tumor or mammary reduction test material
R10 C20 C18 coref-other the malignant tumor material,tissue obtained from malignant mammary tumors
R11 C21 C4 coref-ident platelet aggregation,platelet aggregation
R12 C24 C23 coref-ident arachidonic acid aggregation,arachidonic acid aggregation
R13 C25 C17 coref-ident ADP aggregation,benign tumor or mammary reduction test material
R14 C26 C20 coref-ident material from mammary cancer patients,the malignant tumor material
R15 C29 C27 coref-pron that,material
R16 C28 C19 coref-ident that in benign mammary tissue,the non-tumor material

pubmed-sentences-benchmark

Id Subject Object Predicate Lexical cue
S1 0-66 Sentence denotes Eicosanoids in breast cancer patients before and after mastectomy.
S2 67-208 Sentence denotes In 19 patients with a malignant breast tumor, tumor tissue and blood were taken to determine the eicosanoid profile and platelet aggregation.
S3 209-323 Sentence denotes Values were compared with those of patients with benign tumors (n = 4), or undergoing a mammary reduction (n = 7).
S4 324-415 Sentence denotes Postoperatively, blood was taken as well in order to compare pre- and postoperative values.
S5 416-579 Sentence denotes Eicosanoids were measured in peripheral blood monocytes and mammary tissue by means of HPLC; furthermore, TXA2, 6-keto-PGF1 alpha, and PGE2 were determined by RIA.
S6 580-843 Sentence denotes Differences in pre- and postoperative values of cancer patients were seen in plasma RIA values: PGE2 and 6-k-PGF1 alpha were significantly higher preoperatively when compared with postoperatively, however, such differences were seen in the control groups as well.
S7 844-1005 Sentence denotes Compared to benign tumor or mammary reduction test material the eicosanoid profile of tissue obtained from malignant mammary tumors showed important differences.
S8 1006-1237 Sentence denotes Except for PGF2 alpha, HHT and 15-HETE no detectable quantities of eicosanoids were found in the non-tumor material, whereas in the malignant tumor material substantial quantities of a number of eicosanoid metabolites were present.
S9 1238-1619 Sentence denotes Statistically significant correlations could be established between patient/histopathology data and the results of the platelet aggregation assays, e.g. between menopausal status and ADP aggregation; oestrogen receptor (+/-) and collagen and arachidonic acid aggregation, inflammatory cell infiltration score and arachidonic acid aggregation and fibrosis score and ADP aggregation.
S10 1620-1752 Sentence denotes The results show that eicosanoid synthesis in material from mammary cancer patients is different from that in benign mammary tissue.
S11 1753-1849 Sentence denotes The implications, in particular, in relation to future prognosis of the patient, remain obscure.

GENIAcorpus

Id Subject Object Predicate Lexical cue
T1 0-11 lipid denotes Eicosanoids
T2 15-37 multi_cell denotes breast cancer patients
T3 55-65 other_name denotes mastectomy
T4 73-81 multi_cell denotes patients
T5 89-111 other_name denotes malignant breast tumor
T6 113-125 tissue denotes tumor tissue
T7 130-135 tissue denotes blood
T8 164-174 lipid denotes eicosanoid
T9 187-195 cell_type denotes platelet
T10 244-252 multi_cell denotes patients
T11 258-271 tissue denotes benign tumors
T12 297-314 other_name denotes mammary reduction
T13 341-346 tissue denotes blood
T14 416-427 lipid denotes Eicosanoids
T15 445-471 cell_type denotes peripheral blood monocytes
T16 476-490 tissue denotes mammary tissue
T17 503-507 other_name denotes HPLC
T18 522-526 lipid denotes TXA2
T19 528-545 lipid denotes 6-keto-PGF1 alpha
T20 551-555 lipid denotes PGE2
T21 575-578 other_name denotes RIA
T22 628-634 multi_cell denotes cancer
T23 635-643 multi_cell denotes patients
T24 657-663 other_name denotes plasma
T25 664-674 other_name denotes RIA values
T26 676-680 lipid denotes PGE2
T27 685-699 lipid denotes 6-k-PGF1 alpha
T28 820-834 multi_cell denotes control groups
T29 856-868 tissue denotes benign tumor
T30 872-903 other_name denotes mammary reduction test material
T31 908-918 lipid denotes eicosanoid
T32 930-936 tissue denotes tissue
T33 951-975 tissue denotes malignant mammary tumors
T34 1017-1027 lipid denotes PGF2 alpha
T35 1029-1032 lipid denotes HHT
T36 1037-1044 lipid denotes 15-HETE
T37 1073-1084 lipid denotes eicosanoids
T38 1103-1121 tissue denotes non-tumor material
T39 1138-1162 tissue denotes malignant tumor material
T40 1201-1211 lipid denotes eicosanoid
T41 1306-1333 other_name denotes patient/histopathology data
T42 1357-1365 cell_type denotes platelet
T43 1399-1416 other_name denotes menopausal status
T44 1421-1424 nucleotide denotes ADP
T45 1438-1456 protein_family_or_group denotes oestrogen receptor
T46 1467-1475 protein_family_or_group denotes collagen
T47 1480-1496 lipid denotes arachidonic acid
T48 1510-1546 other_name denotes inflammatory cell infiltration score
T49 1551-1567 lipid denotes arachidonic acid
T50 1584-1598 other_name denotes fibrosis score
T51 1603-1606 nucleotide denotes ADP
T52 1642-1652 lipid denotes eicosanoid
T53 1680-1694 multi_cell denotes mammary cancer
T54 1695-1703 multi_cell denotes patients
T55 1737-1751 tissue denotes mammary tissue
T56 1825-1832 multi_cell denotes patient